Compass Submits Psilocybin Depression Drug To FDA
Pharmaceutical company Compass Pathways announced Monday that it had submitted to the U.S. Food and Drug Administration a new drug application to treat treatment-resistant depression with psilocybin, the primary compound in psychoactive...To view the full article, register now.
Already a subscriber? Click here to view full article